ClinicalTrials.gg
Active, not recruitingNCT04944979KIDCARES10Updated May 29, 2026

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

A Phase 3 interventional study of Kedrion IVIG 10% in Primary Immunodeficiency Disease, sponsored by Kedrion S.p.A.. Active, not recruiting at 21 sites in 6 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Kedrion S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Planned enrollment
17th of 26
30 · median 45
Started
2021
with 1 other
Phase 3
18 of 27
2 open now
Registered
25th of 27
by date
Lead sponsor
3 of 27
Kedrion S.p.A.

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2021, is one of 18 in phase 3, and was the 25th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).

03

Conditions studied

  • Primary Immunodeficiency Disease

Keywords

  • Immunoglobulin
  • Kedrion IVIG 10%
  • IgG Antibodies
  • Agammaglobulinemia
  • Hypogammaglobulinemia
  • Pediatric
04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written /assent obtained from the patient and his/her parent(s) or legally acceptable representative indicating that they understand the purpose of and procedures required for the study and are willing to participate in it.
  2. Confirmed clinical diagnosis of a PID as defined by 2017 International Union of Immunological Societies (IUIS) Phenotypic Classification for Primary Immunodeficiencies (Bousfiha A, 2018 - and subsequent revisions) and The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity (Seidel MG et al., 2019 - and subsequent revisions) and requiring treatment with IVIg. Documented agammaglobulinemia (defined as the total absence of one or more classes of antibodies) or hypogammaglobulinemia (defined as low levels of one or more classes [i.e., at least 2 standard deviations under the mean level per age]).

    (NOTE: IVIg treatment is generally requested in the absence of IgG independently from whether other antibodies are absent).

  3. Male or female, age from 2 up to \< 16 years, at the time of screening.
  4. Received 200 to 800 mg/kg of a commercially available IVIg therapy in the range of 21- or 28-day intervals (±3 or ±4 days, respectively) for at least 3 infusions prior to screening.

    (NOTE: Other IVIgs will be prohibited after ICF signature and until study end, week 51/52).

  5. At least 2 documented IgG trough levels while receiving an IVIg, of ≥ 6 g/L obtained at 2 infusions within 12 months (1 must be within 6 months) prior to ICF signature.
  6. Patient and his/her parent(s)/legal guardian(s) are willing to comply with all requirements of the protocol.
  7. Females of with a negative pregnancy test (serum or urine) and who agree to employ adequate measures during the study, such as:

    1. sexual abstinence, to be evaluated in relation to the preferred and usual lifestyle of the subject;
    2. male or female condom with or without spermicide;
    3. cap, diaphragm or sponge with spermicide;
    4. progestogen-only oral hormonal contraception, if already used in the past on medical prescription.

    Adequate birth control measures should be maintained throughout the study under parental control.

  8. Authorization to access personal health information.
  9. Patients previously participating in a clinical trial with another experimental IVIg may be enrolled if they have received stable commercially available IVIg therapy for at least 3 infusions (21 or 28 days) prior to screening.
  10. Patients currently on treatment with any subcutaneous immunoglobulin (SCIG) can be enrolled if they are switched to stable commercially available IVIg therapy for at least 3 infusions (21 or 28 days) prior to screening.
  11. Males or females with a body weight greater than or equal to 15 kg (≥ 15 kg).

Exclusion criteria

Exclusion Criteria:

  1. Newly diagnosed PID and naïve to IgG replacement therapy.
  2. Dysgammaglobulinemia (defined as a deficiency in one or more classes of antibodies, but not severe enough to require substitutive therapy) or isolated IgG subclass deficiency, or profound primary T cell deficiency (defined as the absence or severe reduction of T lymphocytes [CD3+ \< 300 cell/mm3] and an absent or particularly low proliferative response [10% of the lower normal range] to phytohaemagglutinin P [PHA]).
  3. History of severe or serious reactions or to IVIg or other injectable forms of IgG.
  4. History of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, , or myocardial infarction, as defined by at least 1 event in patient's lifetime.
  5. IgA deficiency with documented antibodies to IgA.
  6. Received blood products that have not undergone viral inactivation measures within 12 months prior to ICF signature.
  7. Significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia.
  8. An acute infection as documented by culture or diagnostic imaging and/or a body temperature ≥38.5 °C (≥101.3 °F) within 7 days prior to screening.
  9. Acquired immunodeficiency syndrome (AIDS) and/or /C active disease at ICF signature.
  10. (ALT) or aspartate aminotransferase (AST) > 2.5 times of the for the laboratory designated for the study.
  11. Using an implanted venous access device.
  12. Moderate or severe anemia, defined according to patient's age as shown in the following table (World Health Organization, 2011) or persistent severe neutropenia (≤ 500 neutrophils per mm3) or persistent lymphopenia of less than 500 cells per microliter.
  13. A severe chronic condition such as renal failure [defined as abnormalities in kidney structure or function that are present for more than 3 months and have health implications. The disease is classified on the basis of cause and category of (GFR) (G1 to G5) and albuminuria (A1 to A3) (KIDIGO, 2017). See the following table], congestive heart failure ( III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity, or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
  14. History of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to ICF signature.
  15. History of pharmacoresistant epilepsy or multiple episodes of migraine (defined as at least 1 episode within 6 months of ICF signature) not controlled by medication.
  16. Patient must not be receiving the following medication from at least 30 days prior to ICF signature:

    1. , inhaled, oral or parenteral, at a daily dosage of ≥ 0.15 mg/kg/day of prednisone or equivalent).
    2. Other drugs (including monoclonal antibodies) or chemotherapy.
  17. Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
  18. Participated in another clinical study within 30 days prior to ICF signature.
  19. Active drug or alcohol abuse or history of drug or alcohol abuse within the 6 months before screening.
  20. Direct relative of an employee of the CRO, the study site, or Kedrion.
  21. Previously treated under this protocol.
  22. Unable to provide .
  23. Patients with any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives or the patient's participation in this trial.
  24. Patients with Hypersensitivity to the active substance or to any of the .
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental: Kedrion IVIG 10%

    Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.

    Biological: Kedrion IVIG 10%

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence Rate of Acute Serious Bacterial Infections

    Incidence rate (i.e., the mean number of acute serious bacterial infections per patientyear) of acute serious bacterial infections (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) according to pre-specified criteria).

    Time frame: From Baseline (Day 1) up to week 51/52

Secondary outcomes

  1. Serum Immunoglobulin G (IgG) trough levels

    Time frame: Before each infusion of KIg10 and at the study termination visit (Week 51/52)

  2. Immunoglobulin G (IgG) subclasses levels (IgG1, IgG2, IgG3, IgG4)

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule, and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  3. Frequency of patients with total Immunoglobulin G (IgG) below 6 g/L

    Time frame: Day 1 up to week 51/52

  4. Anti-tetanus toxoid antibody level

    The quantitative evaluation will be reported

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  5. Anti-pneumococcal capsular polysaccharide antibody level

    The quantitative evaluation will be reported

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  6. Anti-measles antibody level

    The quantitative evaluation will be reported

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  7. Anti-Haemophilus influenza type b antibody level

    The quantitative evaluation will be reported

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  8. Incidence rate (i.e., the mean number per patient-year) of any infection other than acute serious bacterial infections

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  9. Duration of any infection other than acute serious bacterial infections

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  10. Incidence rate (i.e. the mean number per patient-year) of fever episodes

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  11. Duration of fever episodes

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  12. Overall hospitalization days

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  13. Days of hospitalizations due to infection

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  14. Incidence rate (i.e. the mean number per patient-year) of patient on antibiotics for the treatment of any kind of infection

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  15. Duration of patients on antibiotics for the treatment of any kind of infection

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  16. Days of missed work/school/other major activities due to infections

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  17. Pediatric Quality of Life Inventory (Pedsql) Score

    The PedsQL™ Measurement Model is a modular approach to measuring health-related QoL in healthy children and adolescents and those with acute and chronic health conditions. The 23-item PedsQL™ Generic Core Scales were designed to measure the core dimension of health as delineated by the World Health Organization, as well as role (school) functioning. The total scale score (23 items) consists of Physical health summary score (8 items) and Psychosocial health summary score (15 items). Physical health summary includes Physical Functioning (8 items) and Psychosocial health summary score includes Emotional Functioning (5 items), Social Functioning (5 items) and School Functioning (5 items). The overall range for PedsQL scores is 0 to 100, with a higher score indicating better quality of life.

    Time frame: At baseline, week 24, and study termination visit

  18. Number of Adverse Events (%) and proportion of patients experiencing at least one Adverse Event (AE)

    Time frame: From Baseline (Day 1) up to Week 51/52

  19. Number of Serisous AEs (%) and proportion of patients experiencing at least one Serious Adverse Event (SAE)

    Time frame: From Baseline (Day 1) up to Week 51/52

  20. Number of related infusion AEs (%) occurring during infusion or within 1, 24, and 72 hours after the end of infusion, and proportion of patients experiencing at least one related infusion AE. at least 1 of such related infusion AE.

    Time frame: From Baseline (Day 1) up to Week 51/52

  21. The proportion and number of KIg10 infusions for which the infusion rate is decreased due to Adverse Events.

    Time frame: From Baseline (Day 1) up to Week 51/52

  22. Number and proportion of infusions with one or more infusion (temporally-associated) Adverse Event.

    Time frame: From Baseline (Day 1) up to Week 51/52

  23. Number of Participants with Changes from Baseline Values in Vital Signs, Physical Examinations, Safety Laboratory Tests (hematology, serum chemistry and urinalysis).

    Number of participants with changes from baseline in vital signs (including blood pressure, heart rate and temperature); Physical examination (including evaluation of all body systems, body weight, height and Tanner Staging); Safety Laboratory Tests (including hematology, serum chemistry, and urinalysis) will be reported.

    Time frame: Up to Week 51/52

  24. The proportion and number of patients with a positive Coomb's test

    Time frame: Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21-day infusion schedule

  25. The proportion and number of patients with a positive urine hemosiderin test

    Time frame: Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21- day infusion schedule

  26. Serum haptoglobin level

    Time frame: Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21-day infusion schedule.

  27. Serum Total Immunoglobulin G (IgG) levels, IgG Subclasses Levels, and Selected Specific Antibody Levels

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  28. Plasma Concentration - Time Curve Of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  29. Elimination Half-Life (t1/2) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  30. Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  31. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC[0-inf]) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  32. Volume of Distribution of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  33. Maximum Observed Plasma Concentration (Cmax) Of Total IgG

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  34. Time to Reach the Maximum Plasma Concentration (Tmax) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  35. Elimination Rate Constant of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  36. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-Tau) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  37. Plasma Concentration-Time Curve Of Specific Immunoglobulin G (IgG) Antibodies

    The quantitative evaluation of the anti-Tetanus toxoid, anti-pneumococcal capsular polysaccharide, anti-Haemophilus influenza type B and anti-measles antibodies level will be reported

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  38. Elimination Half-Life (t1/2) of Specific IgG Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  39. Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  40. Volume Of Distribution of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  41. Maximum Observed Plasma Concentration (Cmax) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  42. Time to Reach the Maximum Plasma Concentration (Tmax) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  43. Elimination Rate Constant of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  44. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-inf]) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  45. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-Tau) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

07

Study locations

21 sites
  • Benioff Children&#39;s Hospital - Mission Bay
    San Francisco, California 94158, United States
  • IMMUNOe Health and Research Centers
    Centennial, Colorado 80112, United States
  • Johns Hopkins All Children's Hospital
    St. Petersburg, Florida 33701, United States
  • Velocity Clinical Research - MedPharmics - Lafayette
    Lafayette, Louisiana 70508, United States
  • Louisiana State University Shreveport
    Shreveport, Louisiana 71103, United States
  • Duke Children's Hospital & Health Center
    Durham, North Carolina 27706, United States
  • Asthma and Allergy Center - Toledo
    Toledo, Ohio 43617, United States
  • Vital Prospects Clinical Research Institute PC
    Tulsa, Oklahoma 74136, United States
  • Dél-Pesti Centrumkórház - Országos Hematológiai És Infektológiai Intézet
    Budapest, Hungary
  • SST Spedali Civili di Brescia
    Brescia, Italy
  • Azienda Ospedaliero-Universitaria - Ospedale Pediatrico Meyer
    Florence, Italy
  • I.R.C.C.S. Istituto Giannina Gaslini
    Genova, Italy
  • Fondazione IRCCS Ca&#39; Granda Ospedale Maggiore Policlinic
    Milan, Italy
  • Azienda Ospedaliera Universitaria &#34;Federico II&#34;
    Naples, Italy
  • Fondazione Policlinico Tor Vergata
    Roma, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesù
    Roma, Italy
  • Centro Hospitalar Lisboa Central - Hospital Dona Estefânia
    Lisbon, Portugal
  • Centro Hospitalar Universitário do Porto - Hospital Santo António
    Porto, Portugal
  • Children&#39;s City Clinical Hospital No. 9 named after G.N. Speransky, Moscow City Health Department
    Moscow, Russia
  • Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
    Moscow, Russia
  • Národný ústav detských chorôb (National Institute of Pediatric Diseases)
    Bratislava, Slovakia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's planned 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jun 30, 2021
StartActual
Mar 31, 2021
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04944979
Lead sponsor
Kedrion S.p.A.
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
Mar 31, 2021
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
May 29, 2026

Study contacts

Chiara Azzari
principal investigator · Azienda Ospedaliero-Universitaria Ospedale Pediatrico Meyer - Italy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion